[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lymph-node-excision\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lymph-node-excision":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,81,108,138],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100589100","safety--performance-of-canopus-pintuition-surgical-marker-navigation-100589100",false,"NCT06950021","Safety & Performance of CANOpus PINtuition Surgical Marker Navigation","Safety & Performance of CANOpus PINtuition Surgical Marker Navigation (CANOPIN)","CANOPIN","Inclusion Criteria:\n\n1. Subject is willing and able to provide informed consent for the investigation\n2. Subject is at least 18 years of age\n3. Subject is diagnosed with a single, pathologically confirmed unifocal breast tumour (DCIS or invasive)\n4. Tumour is ultrasound visible\n5. Subject is indicated for primary breast conserving surgery and\u002For targeted axillary dissection\n6. Subject is indicated for preoperative localization using a single marker in the primary breast lesion and\u002For a single marker in an axillary lymph node\n\nExclusion Criteria:\n\n1. Subject is lactating or pregnant\n2. Subject is expected to have surgery scheduled more than 6 weeks after implantation of the Canopus Marker.\n3. Subject has an ICD or other active implant such as a pacemaker less than 5 cm away from the intended target location(s)\n4. Subject has a proven infection or clinically significant hematoma at or close to the intended target location(s)\n5. Subject is expected to require an MRI scan in the period between implantation and surgery\n6. Known hypersensitivity to Titanium or Nickel","ALL","18 Years",{"count":20,"type":21},35,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to evaluate the safety and performance of the Canopus Marker in adult breast cancer patients who are scheduled for breast-conserving surgery. The main questions it aims to answer are:\n\n1. Can the Canopus Marker be safely and effectively used to mark tissue for surgical removal?\n2. What is the satisfaction level of radiologists, surgeons, and patients with the use of the Canopus Marker?\n\nParticipants will:\n\n* Have the Canopus Marker implanted into the tumor or nearby tissue using ultrasound guidance.\n* Undergo surgery where the Canopus Marker will help guide the surgeon to the tumor, and the marker will be removed along with the tumor. This surgery is performed using an FDA cleared and CE-marked detection device (Sirius Pintuition Detector).\n* Attend a follow-up visit two weeks after surgery to assess any adverse events and overall satisfaction.",[27,28],"Breast Surgery","Lymph Node Excision",[30,31,32,33,34,35],"Breast conserving surgery","magnetic seed localization","pintuition","breast sparing surgery","surgical localization","surgical navigation","NOT_YET_RECRUITING","2025-04-22",{"date":39,"type":40},"2025-04-29","ACTUAL",{"date":42,"type":21},"2025-07-01",{"date":44,"type":21},"2026-02-01",{"name":46,"class":47},"Sirius Medical Systems B.V.","INDUSTRY",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":48},"100584672","application-of-indocyanine-green-tracer-in-d2-lymphadenectomy-of-locally-advanced-gastric-cancer-100584672","NCT06892392","Application of Indocyanine Green Tracer in D2 Lymphadenectomy of Locally Advanced Gastric Cancer","Aplicación Del ICG En La Linfadenectomía D2 Laparoscópica Del Cáncer Gástrico Localmente Avanzado: Ensayo Clínico Aleatorizado Multicéntrico.","Gastri-ICG","Inclusion Criteria:\n\n* T2-T4a, N+, M0 on preoperative study\n* PS 0-1\n* ASA I-III\n* Laparoscopic surgery\n\nExclusion Criteria:\n\n* \\- Previous gastric abdominal surgery\n* DSE\n* Cognitive impairment\n* Allergic to iodine\n* Synchronous neoplasm\n* Stroke in the last 6 months\n* Angina or AMI in the last 6 months\n* Plastic lymphitis\n* Open surgery","85 Years",{"count":59,"type":21},102,[24],"Gastric cancer is a frequent neoplasm in the world, presenting more than one million new cases and around 768,000 deaths in the data registered in 2020. Among the therapeutic options for gastric cancer, surgery is an essential pillar for its treatment. Gastric cancer surgery consists of gastric resection with negative margins and radical lymphadenectomy in patients without distant metastases. It has been demonstrated over the years that radical lymphadenectomy in gastric cancer allows for adequate staging and improved long-term survival.\n\nIn order to perform a correct staging using the TNM system, it is necessary to resect at least 15 lymph nodes in the radical lymphadenectomy. For radical lymphadenectomy staging, the Japanese Gastric Cancer Association defined and subdivided nodal stations. Three types of lymphadenectomy are described according to oncologic gastric resections (D1, D1+ and D2), with D2 lymphadenectomy being the standard of treatment for locally advanced gastric tumors. Performing an insufficient or inadequate lymphadenectomy has been shown to negatively impact survival after gastrectomy in such a cohort.\n\nThe development of technology based on fluorescence guided by indocyanine green could improve the technique and results of D2 lymphadenectomy in patients with gastric cancer. There is evidence that the application of ICG in D2 lymphadenectomy increases the number of resected nodes, however, studies of higher scientific quality (randomized clinical trials) are needed. Furthermore, most studies in this field have focused on Eastern countries (Japan, Korea and China), where the percentage of early tumors and chemotherapy treatment is different from Western centers.\n\nTherefore, we propose a multicenter randomized clinical trial aimed at evaluating whether the application of ICG-guided fluorescence-based technology in D2 lymphadenectomy of locally advanced gastric cancer increases the number of resected nodes, improves the oncologic quality of the lymphadenectomy, and thus may increase overall survival and disease-free survival at 2 and 5 years postoperatively.",[63,64,28,65,66],"GASTRIC CANCER","Indocyanine Green (ICG)","Lymphadenectomy","Laparoscopic Gastrectomy",[68,69,70],"Multicenter randomized 1:1 clinical trial","indocyanine green","Laparoscopic gastrectomy with D2 lymphadenectomy","2025-03-18",{"date":73,"type":40},"2025-03-24",{"date":75,"type":21},"2026-03-01",{"date":77,"type":21},"2032-12",{"name":79,"class":80},"Hospital of Navarra","OTHER",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":48},"100410996","mediastinal-lymph-node-dissection-versus-spared-mediastinal-lymph-node-dissection-in-stage-i-ggn-nsclc-100410996","NCT04631770","Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLC","Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage IA Non-small Cell Lung Cancer Presented as Ground-glass Nodules: Study Protocol of a Phase III, Randomized, Multi-center Trial (MELDSIG) in China","Inclusion Criteria:\n\n* Thin-slice HRCT shows single GGN with C\u002FT ≤ 0.5 and no lymph node metastasis;\n* Clinical stage IA NSCLC (TNM 8th classification) diagnosed prior or in surgery;\n* No history of malignancies within past 5 years or lung surgery;\n* No anti-cancer treatment prior to surgery.\n\nExclusion Criteria:\n\n* Simultaneous or metachronous (within the past 5 years) double cancers;\n* Active bacterial or fungous infection;\n* Interstitial pneumonitis, pulmonary fibrosis, or severe pulmonary emphysema;\n* Systemic steroidal medication;\n* Uncontrollable diabetes mellitus; (vi) Uncontrollable hypertension or history of severe heart disease, heart failure.",{"count":89,"type":21},1362,[24],"Lung cancer is the leading cause of cancer related death worldwide. Lobectomy or sub-lobectomy with mediastinal lymph node dissection is the standard surgery. About 50% lung nodules are pure ground-glass or part-solid nodules. Non-solid nodules rarely develop mediastinal lymph node metastasis. The present study is a prospective, multicenter and randomized clinical trial, comparing the overall survival and disease-free survival of whether performing mediastinal lymph node dissection in non-small cell lung cancer with ground-glass nodule CT features.",[93,28],"Lung Neoplasms",[95,96,97],"Non-small cell lung cancer","Mediastinal lymph node dissection","Ground-glass nodules","RECRUITING","2023-09-24",{"date":101,"type":40},"2023-09-28",{"date":103,"type":40},"2022-05-01",{"date":105,"type":21},"2029-05-01",{"name":107,"class":80},"Tianjin Medical University Cancer Institute and Hospital",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":119,"briefSummary":120,"conditions":121,"keywords":124,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":137},"100495392","fluorescence-laparoscopic-navigation-for-rectal-cancer-and-sigmoid-colon-cancer-100495392","NCT05730595","Fluorescence Laparoscopic Navigation for Rectal Cancer and Sigmoid Colon Cancer","A Randomized Controlled Trial of Fluorescence Laparoscopic Navigation of the Extent of Lymph Node Dissection for High Rectal Cancer and Sigmoid Colon Cancer","FLORA-01","Inclusion Criteria:\n\n* Participants are aged 18-75;\n* Colonoscopy biopsy confirms colorectal adenocarcinoma;\n* Colonoscopy shows that the lower edge of the tumor is located more than 10 cm from the margin or the tumor is located in the upper rectum and sigmoid colon by imaging diagnosis;\n* The tumor is staged cT1-4aNxM0 by preoperative imaging;\n* Participants have no local complications before surgery.\n\nExclusion Criteria:\n\n* Previous history of malignant colorectal tumor;\n* Multiple primary colorectal tumors;\n* Preoperative imaging reveals suspicious positive lymph nodes in the submesenteric artery root region (area 253);\n* Patients undergoing neoadjuvant therapy before surgery;\n* With contraindications to laparoscopic surgery;\n* Histoty of multiple abdominal and pelvic surgery or extensive abdominal adhesions;\n* Other malignancies were diagnosed within the past 5 years;\n* History of severe mental illness;\n* Pregnant or lactating women;\n* With uncontrolled infection before surgery.","75 Years",{"count":118,"type":21},550,[24],"To explore the short-term and long-term outcomes of fluorescence laparoscopic navigation D2 lymph node dissection for colorectal cancer surgery by comparing it with D3 lymph node dissection.",[122,123,28],"Colorectal Neoplasms","Fluorescence",[125,126,127],"Colorectal cancer","Fluorescence laparoscopic navigation","Lymph node dissection","2023-08-26",{"date":130,"type":40},"2023-08-29",{"date":132,"type":21},"2023-09-01",{"date":134,"type":21},"2027-06-01",{"name":136,"class":80},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",19,{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":148,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":48},"100449230","chemoradiotherapy-sequenced-radical-surgery-for-colorectal-cancer-with-palnm-100449230","NCT05129774","Chemoradiotherapy Sequenced Radical Surgery for Colorectal Cancer With PALNM","Concurrent Chemoradiotherapy Sequenced Radical Surgery for Para-aortic Lymph Node Metastasis of Left-sided Colon and Rectal Cancer","Inclusion Criteria:\n\n* age at enrollment is ≥ 18 and ≤ 75 years\n* ECOG PS 0-1\n* histologically confirmed left-sided colon and rectal carcinoma\n* synchronous para-aortic lymph node metastases confirmed by PET-CT, and located below the level of renal veins and above the bifurcation of iliac artery\n* patients potential to receive surgery and achieve no evidence of disease (NED)\n* able to tolerate surgery\n* providing written informed consent\n\nExclusion Criteria:\n\n* local invasion or distant metastasis other than para-aoritc lymph nodes\n* history of other malignant tumor\n* coupled with severe systematic diseases (recent myocardial infarction, cardiomyopathy, or acute pulmonary infection)\n* emergency surgery","70 Years",{"count":147,"type":21},40,[24],"In left-sided colon and rectal cancer, the occurrence of synchronous para-aortic lymph node metastasis is rare, with the incidence of being approximate 1-2%. Currently, there has been no standard treatment strategy for this situation. The present trial is designed to evaluate the safety and efficacy of para-aortic lymph node dissection for left-sided colon and rectal cancer with synchronous para-aortic lymph node metastasis",[151,28,152],"Colorectal Neoplasms Malignant","Chemoradiotherapy","2021-11-18",{"date":155,"type":40},"2021-11-22",{"date":157,"type":21},"2022-01-01",{"date":159,"type":21},"2027-01-01",{"name":161,"class":80},"Qilu Hospital of Shandong University"]